Articles related to RESEARCH & CLINICAL TRIALS

First randomized evidence supporting feasibility of maintaining cardiac stability with carvedilol alone after systematic withdrawal of other heart failure medications in selected patients.

Research disruption spans 24 institutes with disproportionate impact on minority health disparities and early career investigators.

Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.

DETECT AS trial showed electronic notifications increased AVR rates by 11% overall and 14% in symptomatic patients, while EARLY TAVR analyses confirmed superior outcomes with timely intervention versus surveillance, with biomarkers failing to predict optimal treatment timing.

FRESH-UP found no benefit in health status, hospitalizations, or mortality when restricting fluids to 1,500 mL daily in stable heart failure patients, while significantly increasing thirst distress.

High-dose vitamin D demonstrated a 34% reduced risk of disease activity in both CIS and early RRMS patients, with MRI markers showing particular improvement, though no significant impact on clinical symptoms or disability progression was observed.